Hinova Pharmaceuticals Inc. (SHA:688302)
China · Delayed Price · Currency is CNY 45.10
-0.31 (-0.68%)
At close: Feb 13, 2026
Hinova Pharmaceuticals Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -144.57 | -199.5 | -294.16 | -301.51 | -306.18 | -489.85 |
Depreciation & Amortization | 5.97 | 5.97 | 6.42 | 5.47 | 3.05 | 1.2 |
Other Amortization | 0.04 | 0.04 | 0.04 | 0.04 | 0.63 | 0.62 |
Loss (Gain) From Sale of Assets | 0 | 0 | 0.01 | 0 | 0 | - |
Asset Writedown & Restructuring Costs | - | - | - | - | - | -0.15 |
Loss (Gain) From Sale of Investments | -13.11 | -13.11 | -24.83 | -28.89 | -23.56 | -5.13 |
Stock-Based Compensation | - | - | - | - | - | 91.61 |
Other Operating Activities | 1.69 | -3.66 | -2.78 | -3.3 | 6.05 | 14.96 |
Change in Accounts Receivable | 5.92 | 5.92 | 5.76 | 4.04 | 3.96 | -29.74 |
Change in Inventory | 0 | 0 | 0 | -0 | -0 | -0 |
Change in Accounts Payable | -7.54 | -7.54 | -21.85 | -93.6 | -20.6 | 172.82 |
Change in Other Net Operating Assets | 24.79 | 24.79 | 75.88 | 102.82 | 108.82 | - |
Operating Cash Flow | -126.81 | -187.08 | -255.51 | -314.92 | -227.82 | -243.66 |
Capital Expenditures | -36.93 | -89.55 | -99.18 | -69.21 | -19.77 | -2.5 |
Sale of Property, Plant & Equipment | 0 | 0 | 0.02 | 0 | - | 0 |
Cash Acquisitions | - | - | - | - | - | -0.55 |
Investment in Securities | 10 | 80 | -25 | -370 | - | 3.5 |
Other Investing Activities | 7.99 | -20.7 | 24.83 | 29.31 | 23.2 | 3.86 |
Investing Cash Flow | -18.94 | -30.25 | -99.33 | -409.9 | 3.42 | 8.82 |
Short-Term Debt Issued | - | - | 0.5 | 30 | - | 0.5 |
Total Debt Issued | 100 | - | 0.5 | 30 | - | 0.5 |
Short-Term Debt Repaid | - | - | -30.5 | - | -0.5 | -52.09 |
Long-Term Debt Repaid | - | -4.06 | -4.39 | -3.4 | -1.56 | - |
Total Debt Repaid | -4.06 | -4.06 | -34.89 | -3.4 | -2.06 | -52.09 |
Net Debt Issued (Repaid) | 95.94 | -4.06 | -34.39 | 26.6 | -2.06 | -51.59 |
Issuance of Common Stock | - | - | - | 1,010 | - | 1,421 |
Common Dividends Paid | -0.59 | - | -0.9 | - | -2.56 | -0.36 |
Other Financing Activities | 0.44 | - | - | -19.31 | -3.86 | -10.59 |
Financing Cash Flow | 95.8 | -4.06 | -35.29 | 1,017 | -8.48 | 1,359 |
Foreign Exchange Rate Adjustments | 1.42 | 1.43 | 1.75 | 7.8 | -1.99 | -4.93 |
Net Cash Flow | -48.53 | -219.96 | -388.38 | 300.38 | -234.87 | 1,119 |
Free Cash Flow | -163.74 | -276.63 | -354.68 | -384.13 | -247.6 | -246.16 |
Free Cash Flow Margin | -693.57% | -75410.46% | - | -23269.07% | - | - |
Free Cash Flow Per Share | -1.65 | -2.79 | -3.58 | -4.23 | -3.33 | -3.50 |
Cash Interest Paid | - | - | - | 3.92 | - | 4.51 |
Cash Income Tax Paid | 1.14 | 0.44 | -19.4 | -13.46 | -6.07 | -0.54 |
Levered Free Cash Flow | 295.93 | 268.67 | -230.86 | -252.88 | -145.13 | -120.22 |
Unlevered Free Cash Flow | 296.2 | 269 | -229.93 | -250.43 | -143.54 | -119.99 |
Change in Working Capital | 23.17 | 23.17 | 59.79 | 13.27 | 92.19 | 143.08 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.